CD4 and head and neck squamous cell carcinoma: As patients with recurrent SCCHN are more likely to display abnormalities in their T cell development [23], the drop in CD4+ T cells before start of therapy (t0) appeared to be more pronounced in patients with locoregional recurrence compared to patients who remained free of recurrence [22–24].